Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 14/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | HINT1 | P49773 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20547506 | 0.84 | STING1 (0.51) | STING1PDE3BPDE3A | |
| SCHEMBL6403190 | 0.84 | STING1 (0.44) | STING1 | |
| SCHEMBL6399320 | 0.83 | HINT1 (0.42) | STING1PDE3BPDE3AHINT1 | |
| SCHEMBL6395562 | 0.82 | STING1 (0.63) | STING1PDE3BPDE3A | |
| SCHEMBL20548261 | 0.75 | STING1 (0.43) | STING1PDE3BPDE3A | |
| SCHEMBL14946333 | 0.73 | STING1 (0.43) | STING1PDE3BPDE3A | |
| SCHEMBL20149812 | 0.73 | STING1 (0.43) | STING1PDE3BPDE3A | |
| SCHEMBL6397385 | 0.73 | HINT1 (0.61) | HINT1 | |
| SCHEMBL14946312 | 0.73 | STING1 (0.47) | STING1PDE3BPDE3A | |
| SCHEMBL26780958 | 0.73 | STING1 (0.47) | STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | STING1 2435/4885PDE3B 3098/4885PDE3A 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.